These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 29292693)

  • 21. Clinical Outcomes of Everolimus With Reduced-Dose Tacrolimus vs Mycophenolate Mofetil With Standard-Dose Tacrolimus in De Novo ABO-Incompatible Kidney Transplant Recipients: 1-Year Follow-up.
    Kosoku A; Iwai T; Uchida J
    Transplant Proc; 2022 Mar; 54(2):293-298. PubMed ID: 35031117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Results in Recipients of Late Conversion to a Calcineurin Inhibitor-Free Regimen with Everolimus After Kidney Transplantation.
    Iwahara N; Hotta K; Hirose T; Shinohara N
    Transplant Proc; 2023 May; 55(4):803-808. PubMed ID: 37147197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Outcomes of Everolimus Therapy in De Novo Liver Transplantation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bzeizi KI; Smith R; Albenmousa A; Dama M; Aba-Alkhail F; Jalan R; Broering D
    Transplant Proc; 2021; 53(1):148-158. PubMed ID: 33390288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
    Watarai Y; Danguilan R; Casasola C; Chang SS; Ruangkanchanasetr P; Kee T; Wong HS; Kenmochi T; Amante AJ; Shu KH; Ingsathit A; Bernhardt P; Hernandez-Gutierrez MP; Han DJ; Kim MS
    Clin Transplant; 2021 Oct; 35(10):e14415. PubMed ID: 34216395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients.
    Brunkhorst LC; Fichtner A; Höcker B; Burmeister G; Ahlenstiel-Grunow T; Krupka K; Bald M; Zapf A; Tönshoff B; Pape L
    PLoS One; 2015; 10(9):e0135439. PubMed ID: 26407177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
    Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
    Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Everolimus plus mycophenolate mofetil as initial immunosuppression in liver transplantation.
    Jiménez-Pérez M; González Grande R; Rando Muñoz FJ; de la Cruz Lombardo J; Muñoz Suárez MA; Fernández Aguilar JL; Pérez Daga JA; Santoyo-Santoyo J; Manteca González R; Rodrigo López JM
    Transplant Proc; 2015; 47(1):90-2. PubMed ID: 25645779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-year follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment.
    Hiramitsu T; Okada M; Futamura K; Yamamoto T; Tsujita M; Goto N; Narumi S; Watarai Y; Takeda A; Iwasaki K; Uchida K; Kobayashi T
    Int Immunopharmacol; 2016 Oct; 39():192-198. PubMed ID: 27491025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction.
    Wang P; Que W; Li H; Yan L; Fu Z; Ye Q; Chen G; Dou K; Lu S; Yang Z; Zhu Z; Peng Z; Zhong L
    Oncotarget; 2017 Aug; 8(34):57505-57515. PubMed ID: 28915690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of T-Cell Immune Status of Reduced-Dose Cyclosporine and Everolimus Combination Therapy in Kidney Transplant Patients.
    Tanaka A; Ide K; Tanaka Y; Sasaki Y; Doskali M; Tahara H; Ohira M; Ohdan H
    Transplant Proc; 2023 May; 55(4):797-802. PubMed ID: 37032288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients.
    Mourer JS; de Koning EJ; van Zwet EW; Mallat MJ; Rabelink TJ; de Fijter JW
    Transplantation; 2013 Jul; 96(1):49-57. PubMed ID: 23715049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.
    Sommerer C; Legendre C; Citterio F; Watarai Y; Oberbauer R; Basic-Jukic N; Han J; Gawai A; Bernhardt P; Chadban S
    Transplantation; 2023 Jul; 107(7):1593-1604. PubMed ID: 36959121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
    Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
    Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of everolimus treatment on liver transplant recipients: A meta-analysis.
    Guan TW; Lin YJ; Ou MY; Chen KB
    Eur J Clin Invest; 2019 Dec; 49(12):e13179. PubMed ID: 31610022
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
    Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
    Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
    Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.